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Background: The natural polyphenol myricetin induces cell cycle arrest and apoptosis in preclinical cancer models.
We hypothesised that myricetin-derived flavonoids with enhanced redox properties, improved cell uptake and mitochondrial
targeting might have increased potential as antitumour agents.
Methods:We studied the effect of a second-generation flavonoid analogue Oncamex in a panel of seven breast cancer cell lines,
applying western blotting, gene expression analysis, fluorescence microscopy and immunohistochemistry of xenograft tissue
to investigate its mechanism of action.
Results: Proliferation assays showed that Oncamex treatment for 8 h reduced cell viability and induced cytotoxicity and apoptosis,
concomitant with increased caspase activation. Microarray analysis showed that Oncamex was associated with changes in the
expression of genes controlling cell cycle and apoptosis. Fluorescence microscopy showed the compound’s mitochondrial
targeting and reactive oxygen species-modulating properties, inducing superoxide production at concentrations associated
with antiproliferative effects. A preliminary in vivo study in mice implanted with the MDA-MB-231 breast cancer xenograft showed
that Oncamex inhibited tumour growth, reducing tissue viability and Ki-67 proliferation, with no signs of untoward effects on the
animals.
Conclusions: Oncamex is a novel flavonoid capable of specific mitochondrial delivery and redox modulation. It has shown
antitumour activity in preclinical models of breast cancer, supporting the potential of this prototypic candidate for its continued
development as an anticancer agent.
Flavonoids account for the largest and most ubiquitous group of
plant secondary metabolites. They comprise seven different
subclasses of polyphenols with a common backbone consisting
of two fused rings linked to another aromatic ring (Weng and
Yen, 2012). Beyond their numerous roles in plant biology,
flavonoids have long been identified as possessing a wide range
of bioactivities, including protective and therapeutic effects against
cancer, cardiovascular and neurodegenerative diseases, and thus
have great potential for clinical application (Romano et al, 2013).
In particular, extensive preclinical evidence has accumulated
for their antiproliferative effects against several types of cancer,
including breast (Pan et al, 2012), prostate (Brown et al, 2005),
lung (Park et al, 2012) and colorectal cancers (Ko et al, 2005a).
However, their use in a therapeutic context is presently hampered
by poor drug-like attributes resulting in low bioavailability
and metabolic stability, limited cell uptake and ineffective
delivery to important cellular compartments such as the
mitochondria.
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Previous research has reported the anticancer effect of
flavonoids on breast tumours through multiple mechanisms
(Martinez-Perez et al, 2014). Structural similarities to the hormone
17b-oestradiol allow for interaction with the oestrogen receptors
(ERs) (Limer and Speirs, 2004), although the effect is predomi-
nantly beneficial due to a stronger affinity for the proliferation-
inhibiting isoform ERb (Stro¨m et al, 2004; Harris et al, 2005;
McCarty, 2006). In addition, flavonoids can block the bioactivation
of procarcinogens (Ciolino and Yeh, 1999; Moon et al, 2006) and
act as inhibitors for oestrogen-producing and metabolising
enzymes (Sanderson et al, 2004; Rice and Whitehead, 2006) and
for the breast cancer resistance protein (BCRP), involved in
the development of multidrug resistance (Katayama et al, 2007;
Tan et al, 2013).
Flavonoids exert these antitumour activities in a concentration-
and time-dependent manner, and have been shown to be effective
in the treatment of numerous cancer types specifically targeting
malignant cells (Ramos, 2007). Such properties support flavonoids
as strong candidates for the development of novel anticancer
treatments. Indeed, research has shown that administration of
flavonoids can lead to a decrease in inflammation, proliferation,
tumour size and metastasis (Limer and Speirs, 2004; Peluso et al,
2013). Further potential lies in their application as re-sensitisers in
tumours clinically resistant to TRAIL (tumour necrosis factor-
related apoptosis-inducing ligand) (Siegelin et al, 2009), radio-
therapy (Yi et al, 2008), endocrine therapy (Mai et al, 2007;
Tu et al, 2013) or chemotherapeutic agents like Centchroman
(Singh et al, 2012).
The flavonol myricetin is a natural flavonoid with powerful
antioxidant activity that has been shown to have a therapeutic
effect in different cancers both in vitro and in vivo. It exerts
apoptotic effects in combination with TRAIL (Siegelin et al, 2009)
or by other mitochondrial-dependent pathways (Ko et al, 2005b),
as well as inducing G2/M cell cycle arrest (Zhang et al, 2008). We
hypothesised that myricetin-derived, synthetic flavonoids with
improved antioxidant properties, specific mitochondrial targeting
and optimised physicochemical properties and drug-like attributes
(McPhail et al, 2009) may have enhanced potential as antitumour
agents.
In this study, we characterise a small library of these myricetin-
derived new chemical entities. We assessed their antitumour
properties in a panel of breast cancer cell lines, describing
structure–activity relationships (SARs) and investigating
the mechanism of action of these compounds, including the role
of reactive oxygen species (ROS) modulation in their antitumour
effects. The potential application of such synthetic derivatives
in an in vivo setting was also assessed in a human breast cancer
xenograft model.
MATERIALS AND METHODS
Cell culture. Breast cancer cell lines MCF-7, MDA-MB-231,
BT-549 and HBL-100 (all obtained from ATCC) were cultured
in Dulbecco’s Modified Eagle Medium (DMEM) supplemented
with 10% heat-inactivated foetal calf serum (FCS) and 100 IUml 1
penicillin/streptomycin. These cell lines correspond to different
molecular subtypes of breast cancer, with hormone-dependent
MCF-7 expressing ERs (ERþ ) and MDA-MB-231, BT-549 and
HBL-100 being characterised as triple-negative cell lines, lacking in
receptors for oestrogen, progesterone and human epidermal
growth factor (ER PR HER2 ) and, hence, hormone-
independent. The LCC1, LCC2 and LCC9 (hormone-independent
cells established by derivation of selected subpopulations of MCF-7
cells (Bru¨nner et al, 1993b, 1997; Thompson et al, 1993)) were
cultured in phenol red-free DMEM supplemented with 5% heat-
inactivated FCS charcoal-stripped of steroids. Cells were incubated
at 37 1C in a humidified atmosphere containing 5% CO2. Cells
were grown to confluence with periodic medium changes and
collected by brief incubation with trypsin/ethylenediaminetetraa-
cetic acid solution. All cell lines were authenticated by short
tandem repeat profiling undertaken by the Public Health England
(Salisbury, UK) in December 2014.
Sulforhodamine B assay. Cells (500–2000 cells per well, depend-
ing on doubling time) were typically plated in 96-well microplates,
and medium changed to 2.5% FCS DMEM after 24 h, following
preliminary experiments that showed an improved effect of
drugs for lower serum concentrations (Supplementary Figure 1).
Cells were treated after a further 24 h with a library of eight
compounds, including myricetin and lead compounds AO-1530
and Oncamex (Table 1). Treatments included a range of
micromolar concentrations between 0.01 and 100 mM for all
compounds. Each experiment was repeated at least once.
After treatment cells were fixed with 50 ml per well of cold 25%
trichloroacetic acid for 1 h at 4 1C and washed 10 times with H2O.
After drying, plates were stained for 30min with 50 ml per well of
0.4% (w/v) sulforhodamine B (SRB) (in 1% acetic acid) and washed
four times with 1% acetic acid. Protein-bound SRB was solubilised
in 150 ml per well of 10mM Tris solution (pH 10.5), followed by
measurement of optical density (OD) at 540 nm in a BP800
Microplate Reader (Biohit, Helsinki, Finland). Results were
processed, subtracting average values of blanks and day 0 controls
and normalising to untreated controls.
Fluorescence microscopy. Cells were grown on coverslips and
treated with Oncamex for 15min, 1 or 6 h at 37 1C, adding 25 nM
Mitotracker Deep Red (Life, Eugene, OR, USA) for the last 30min
(or 15min for the shortest incubation). Cells were fixed in 4%
parafarmoldehyde for 45min, washed three times in phosphate-
buffered saline (PBS) and allowed to air-dry before mounting on
Superfrost Plus microscope slides (Thermo Scientific, Braunsch-
weig, Germany) using ProLong Gold antifade mountant with
DAPI (40,6-diamidino-2-phenylindole, Life, Bleiswijk, Nether-
lands). Oncamex possesses fluorescent properties, with a stable
signal measurable at 550 nmEXC/570 nmEM. Cells were visualised,
captures obtained and analysed using a PM-2000 AQUA
(Automated Quantitative Analysis) system (HistoRX, New Haven,
CT, USA) and an Axioplan 2 fluorescence microscope (Zeiss,
Cambridge, UK).
The production of ROS was detected by fluorescence micro-
scopy. The method above was followed with additional staining of
cells with mitochondrial probes following the manufacturers’
guidelines, incubating with 10 mM MitoPY1 (Tocris, Bristol, UK) or
2.5 mM MitoSOX (Life) to detect mitochondrial production of
hydrogen peroxide and superoxide, respectively.
Cell spotting. A total of 105 MCF-7 cells per well were plated in
triplicate in six-well plates. After treatment and incubation, cells
were trypsinised and centrifuged for 5min at 2000 r.p.m. Resulting
pellets were resuspended in 100 ml of FCS and transferred to
Cytofunnels EZ Single (Fisher, Braunschweig, Germany) mounted
on Superfrost Plus slides (VWR International, Leuven, Belgium) to
be spun for 3min at 500 r.p.m. in a Cytospin 4 Cytocentrifuge
(Thermo Fisher, Chesire, UK). Slides were allowed to air-dry and
stained using the Reastain Quick Diff kit (Reagena, Toivala,
Finland), to fix and dye both protein and DNA. After rinsing and
air-drying, cells were observed on an Olympus BX51 microscope
(Olympus, Hamburg, Germany) and images were captured using
the software package Q-Capture Pro (Q Imaging, Surrey, BC,
Canada).
Plate-based assays. The CellTox Green Cytotoxicity and ApoTox-
Glo Triplex assay kits (Promega, Madison, WI, USA) were used to
measure cytotoxicity at different timepoints and to assess the
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mechanism of action of the drugs studied, respectively. In all, 104
cells per well were plated in 96-well microplates (black walls for
CellTox assay and white for ApoTox), changing the medium to
phenol red-free DMEM after 24 h. The protocols were carried out
following the manufacturer’s instructions, and fluorescence and
luminescence were measured in a Labsystems Fluoroskan Ascent
FL (Thermo, Vantaa, Finland) plate reader.
Cell lysates. In all, 3 106 MCF-7 cells per dish were plated in
140-cm2 Petri dishes. After treatment, cells were washed in PBS
and incubated for 10min on ice in 400 ml of lysis buffer (50mM
Tris, 5mM EGTA and 150mM NaCl) containing Complete
Protease Inhibitor Tablet (Roche, Mannheim, Germany; 1 tablet
per 10ml), 1 : 100 of phosphatase inhibitor cocktails 2 and 3
(Sigma, St Louis, MO, USA), 1 : 200 aprotinin (Sigma) and 1 : 100
Table 1. Library of novel flavonoids screened for their antitumour properties
Compound Structure Characteristics/properties
Myricetin Naturally occurring flavonoid identified as particularly powerful antioxidant
AO-1530 Myricetin-based novel flavonoid, mitochondria-targeted and with active redox properties.
Non-redox-active OH groups removed and a decyl chain similar to the one found in vitamin
E has been added to improve permeability and targeting
Oncamex (R1)
AO-1486 (R2)
AO-1487 (R3)
AO-594 (R4)
Bi-methoxylated second-generation analogue of AO-1530
Same backbone as AO-1530, but nonspecific targeting
Same backbone as AO-1530, but nonspecific targeting
Same backbone as AO-1530, but weaker specificity for the mitochondrial compartment
AO-155-179 Similar backbone to that of AO-1530 but one of the fused rings has been removed, leaving a less
flavonoid-like structure
AO-714A Fully blocked redox activity
AO-594 Same backbone as AO-1530, but nonspecific targeting
Abbreviations: R1¼ (CH2)9-CH3; R2¼ (CH2)3-NH-(CH2)4-NH2; R3¼CH2-(C6H8)-NH2.HCl; R4¼no radical; R5¼ (CH2)10-CH3. The addition of different moieties and radicals granted distinctive
redox potential and intracellular targeting to analogues in a library of seven novel, myricetin-derived flavonoids.
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Triton X (Sigma). Lysates were centrifuged at 13 000 r.p.m. at 4 1C
for 6min. Supernatants were recovered and stored at  70 1C.
Bicinchoninic acid assay. Protein concentration in cell lysates was
determined by bicinchoninic acid (BCA) assay. Bovine serum
albumin (BSA, G Biosciences, St Louis, MO, USA) was used as
protein standard, preparing serial dilutions (0–1000 mgml 1) in
distilled water (dH2O), while aliquots of cell lysates were also
diluted 1 : 10 in dH2O. A volume of 1ml of a 1 : 50 copper
sulphate : BCA solution was added to 50 ml of each protein solution
in borosilicate glass tubes. Tubes were incubated at 60 1C for
15min before cooling briefly and dispensing replicates of each
solution to a 96-well microplate. The OD at 540 nM was measured
in a BP800 Microplate Reader (Biohit) and protein concentration
in each lysate was extrapolated from BSA dilutions standard
curves.
Electrophoresis and western blot. Cell lysates (40 mg of protein in
1 : 4 volume of 5 loading buffer (5% SDS, 25% 2-mercaptoetha-
nol, 50% glycerol, 0.02% bromophenol blue and 0.04M Tris)) were
denatured at 60 1C for 1 h and electrophoretically separated by
polyacrylamide gel electrophoresis on Mini-gel equipment
(BioRad, Hemel Hempstead, UK). Prestained protein marker,
Broad Range (7–175 kDa, New England BioLabs, Ipswich, MA,
USA), diluted 1 : 3 in 1 loading buffer, was used as marker.
Proteins were transferred to a polyvinylidene fluoride mem-
brane for 90min at a constant voltage of 100V and in cold, stirred
transfer buffer (25mM Tris and 19.2mM glycine). After blocking
for 1 h at 4 1C in BB : PBS (1 : 1 dilution of Odyssey Blocking buffer
(Li-Cor, Lincoln, NE, USA) in PBS), membranes were incubated
with mouse anti-cleaved PARP (poly(ADP-ribose) polymerase;
1 : 8000 dilution, Cell Signaling, Hitching, UK) and rabbit anti-
human b-tubulin (1 : 6000 dilution, Abcam, Cambridge, UK)
antibodies overnight at 4 1C. Staining with secondary goat anti-
mouse IRDye 800CW and goat anti-rabbit IRDye 680CW
antibodies (both 1 : 10 000 dilution, Li-Cor) was followed by
scanning on Li-Cor Odyssey Scanner (Li-Cor).
Analytical electrochemistry. To prepare solutions of analytes,
0.5mg of solid sample was suspended in 1ml of 100mM
tetrabutylammonium hexafluorophosphate dissolved in acetoni-
trile (MeCN), and the suspension was treated with ultrasound in a
water bath (40 1C) for 30min. Cyclic voltammograms were
acquired using a Autolab PGStat (Eco-Chemie, Utrecht, Nether-
lands) at a scan rate of 100mV s 1, using only the tenth and final
scan unless otherwise stated, to estimate the reduction potential of
the analytes. A saturated calomel (Hg2Cl2) electrode was used as a
reference and a fine platinum gauze (0.1mm wire, 1 cm2) as a
counter electrode. A straight platinum wire (1mm diameter) was
used as a working electrode, and the experiments were carried out
under a blanket of argon.
RNA processing, microarray hybridisation and data analysis.
Raw and normalised gene expression files are available from the
National Center for Biotechnology Information Gene Expression
Omnibus (Barrett et al, 2005) under the accession number
GSE70949.
Ten samples were collected comprising five breast cancer cell
lines (MCF-7, MDA-MB-231, LCC1, LCC2 and LCC9) in two
different conditions: untreated vehicle control (DMSO) and treated
cells (6 h in 10 mM Oncamex). For this, 3 106 cells per cell line
were treated, trypsinised and stored at  70 1C. The RNA was
extracted using the Qiagen RNeasy Mini kit (Qiagen, Hilden,
Germany), amplified and labelled using the Ambion Illumina
TotalPrep RNA Amplification kit (Life, Carslbad, CA, USA)
(in both steps as per the manufacturers’ instructions) and
hybridised to HumanHT-12 v4 Illumina BeadChips (Illumina,
Cambridge, UK). Arrays were scanned using an Illumina iScan
(Illumina).
Raw gene expression files were log2-transformed and quantile-
normalised using the lumi Bioconductor package (Du et al, 2008),
mapped to Ensembl gene identifiers and detection-filtered using
re-annotation and pre-processing approaches previously described
(Turnbull et al, 2012). Differential gene expression analysis was
performed using pair-wise rank products (Breitling et al, 2004)
between control and treated groups. Functional enrichment
analysis of differentially expressed genes was performed using
DAVID (Database for Annotation, Visualization and Integrated
Discovery) Bioinformatics Resources 6.7 (Huang et al, 2009a, b).
Heatmaps of differentially expressed genes belonging to clusters
enriched for cell cycle and apoptosis were generated using log2 fold
change expression values calculated between treated and control
conditions for each cell line. Heatmaps were generated using TM4
microarray software suite’s MultiExperiment Viewer (Saeed et al,
2003, 2006) and genes were ordered by Euclidean distance. Genes
belonging to the apoptosis cluster were differentiated into pro- and
anti-apoptosis clusters using Qiagen’s custom referenced apoptosis
PCR array literature (references therein).
Xenograft experiments. The xenograft studies were undertaken
under a UK Home Office Project Licence in accordance with the
Animals (Scientific Procedures) Act 1986, and studies were
approved by the University of Edinburgh Animal Ethics Commit-
tee. The MDA-MB-231 xenografts were implanted subcutaneously
into the flanks of adult (48 weeks) female CD-1 immunodeficient
mice (Charles River Laboratories, Tranent, UK), using 10
xenografts per experimental group of 6 mice, implanted in one
or both flanks. Treatment was started when the mean tumour
volume reached 0.25 cm3 (day 0) and mice were treated daily
intraperitoneally with Oncamex (25mg kg 1 per day) or with
solvent control (10% DMSO in saline) on days 0–4 and 7–11.
Changes in tumour size over 14 days were measured using Vernier
callipers and volumes calculated (V¼ lw2/2). Changes in mean
body weight were recorded every 2 days over 14 days. The initial
dose selection of 25mg kg 1 per day was based on the similarity of
this structure to another compound for which 25mk kg 1 per day
had been a safe dose. This dose was confirmed to be safe in
an initial dose-testing experiment and no untoward effects
were noted.
Immunohistochemistry. Xenograft tissue was collected, fixed in
formalin and embedded in paraffin. Sections were dewaxed in
xylene for 5min and washed in alcohol and water before
incubating in heated antigen retrieval solution (0.1M sodium
citrate and 0.1M citric acid, pH 6). Slides were washed in PBS,
incubated in 3% dH2O2 for 10min and washed again in PBST
(0.1% Tween-20 PBS) before incubating for 10min in Total
Protein Block (Dako, Ely, UK). Sections were incubated for 1 h in
mouse monoclonal anti-Ki-67 antibody (1 : 300 dilution, Dako),
followed by 30min in Envision labelled polymer (Dako) and
10min in DAB (1 : 50 dilution in buffer, Dako), with washes in
PBST between each step. Finally, slides were counterstained in
haematoxylin for 1min and taken through graded alcohols to
xylene before mounting in DPX mountant medium (Sigma-
Aldrich, Dorset, UK).
Immunohistochemistry (IHC) scores were calculated by count-
ing average positively stained cells across sections for each of the 10
xenografts for treated and control groups, using the average of
calculations by three users to ensure unbiased estimations.
Percentage of viability was assessed using the image-processing
package Image J (NIH, Bethesda, MD, USA) to measure the viable
areas in each section.
Other materials. Novel flavonoids tested (Table 1) were supplied
by Antoxis Limited (Aberdeen, UK) from their library of
proprietary compounds (Caldwell et al, 2007). They were custom
synthesised and their purity was ascertained to be495% by liquid
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chromatography mass spectrometry and nuclear magnetic reso-
nance. Unless otherwise stated, any other reagents and solvents
were of analytical grade from Sigma-Aldrich and were used
without further purification.
Statistical analysis. For analysis of SRB and other plate-based
assays, all experiments were repeated at least once, and six
technical replicates were used to calculate means and s.d. Results
were processed, subtracting average values of blanks and day 0
controls and normalising to untreated controls. Cell proliferation
curves were fitted to a model for sigmoidal regression using the
Excel package Fit Designer 2D (IDBS, Guildford, UK), excluding
outliers outside of a 95% confidence interval, for the calculation of
half maximal inhibitory concentration (IC50) values.
For statistical analysis of xenograft and IHC results, Prism 6
(GraphPad Software, La Jolla, CA, USA) was used to compare
control and treated groups using unpaired t-test.
RESULTS
Novel flavonoid Oncamex exerts a potent antitumour effect in
breast cancer cell lines. Among the eight compounds tested
(Table 1) in a panel of SRB assays, AO-1530 and its second-
generation methoxylated analogue Oncamex showed the strongest
antiproliferative effects (Figure 1A and B). Oncamex was the most
potent myricetin derivative of the series tested and exerted similar
antiproliferative responses in MCF-7, BT-549, MDA-MB-231 and
HBL-100 cells. For hormone-independent cell lines LCC1, LCC2
and LCC9, the two lead compounds were still more effective than
myricetin although the overall effect was weaker.
Oncamex’s IC50 values were between 4- and 140-fold lower than
those of myricetin in all cell lines, while the potency and IC50
values of the other analogues were more variable (Figure 1C and D).
Analogues AO-714A and AO-155-179 typically exerted antiproli-
ferative effects closer to those of the lead compounds, whereas
other analogues exerted weaker effects, with IC50 values closer to,
or even higher, than those of myricetin.
Oncamex specifically targets the mitochondrial compartment,
with rapid delivery and stable accumulation. Drug uptake and
intracellular location was assessed by microscopic visualisation.
Images obtained demonstrated a specific targeting of the
mitochondrial compartment by Oncamex in the model breast
cancer cell line MDA-MB-231 (selected for its better adherence
when grown on coverslips; Figure 2). The compound was
co-localised with Mitotracker (and absent from nuclei and
cytoplasm) as early as 15min after treatment and was still retained
in the mitochondrial compartment after 6 h. Previous work in
another cancer cell line has shown the ability of AO-1530 to target
the mitochondria, whilst other analogues with weaker antiproli-
ferative effects have less specific intracellular localisation
(Supplementary Figure 2).
Oncamex exerts its antitumour effect through induction of
cytotoxicity and apoptosis. Microscopic observation of MCF-7
cells showed that treatment with Oncamex induced substantial
changes after 24 h, including a reduction of cell density and
division, alterations in nuclear morphology and appearance of
apoptotic cells (Figure 3A–D). By 72 h after treatment these
changes were generalised, with abundant apoptotic, phagocytised
and dead cells. These results suggested the involvement of
apoptosis in Oncamex’s mechanism of action.
A
–0.2
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
O
D 
m
ea
su
re
m
en
t a
t 5
40
 n
m
Compound concentration (µM)
Oncamex
AO-1530
AO-155
AO-1487
AO-714A
Myricetin
AO-1486
AO-594
–1.0
–0.5
0.0
0.5
1.0
1.5
O
D 
m
ea
su
re
m
en
t a
t 5
40
 n
m
Compound concentration (µM)
B
C
Oncamex
AO-1530
Myricetin0.0
15.0
30.0
45.0
60.0
75.0
90.0
IC
50
 
va
lu
es
 (µ
m
)
D
LCC1 16.1685
Myricetin AO-1530 Oncamex
14.4491 1.8831 0.5374
59.3500 4.0611 0.4150
43.3088 12.2097 2.4504
19.0746 2.7173 0.7424
79.9474 24.5072 5.1804
13.4483 22.9500 1.3547
21.1700 3.9692
LCC2
LCC9
MCF-7
MDA-MB-231
HBL-100
BT-549
0.0
1 0.1 1 10 10
0
0.0
1
0.1 1 10 10
0
LC
C1
LC
C2
LC
C9
MC
F-7
MD
A-
MB
-23
1
HB
L-1
00
BT
-54
9
Figure 1. Antitumour effect of Oncamex on breast cancer cell lines. The antiproliferative effect of a library of novel flavonoids was first assessed
through SRB assays on a panel of seven breast cancer cell lines. Cells were treated for 4 days with drug concentrations in the 0.01–100mM range
concentration in all treatments. Results were comparable in all models, including MCF-7 (A) and MDA-MB-231 cells (B), with second-generation
analogue Oncamex showing the strongest anticancer properties, markedly greater than those of myricetin. Analysis of concentration–response
curves obtained from SRB assays allowed for the calculation of IC50 values for myricetin and the lead compounds (C, D), which reflected the
stronger potency of Oncamex.
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SRB assays on cells exposed to different lengths of treatment (8,
16, 24, 48, 72 and 96 h) provided an insight into the timing of the
anticancer effects observed (Supplementary Figure 3). Results
showed that besides the more potent effect of Oncamex over AO-
1530, the former also exerts a more rapid effect, inducing a
significant reduction in cell density after 8 h comparable to the
levels observed after 96 h, whereas AO-1530’s effect was weaker
and more delayed, not affecting cells until 24 h into treatment.
CellTox plate assays showed that Oncamex produced an increase
in cytotoxicity by 8 h after treatment in all cell lines (or earlier in
some of them), reaching levels between 2- and 10-fold greater than
the baseline signal by 24 h (Figure 3E).
Further investigation of Oncamex’s mechanism of action using
ApoTox multiplex assays showed that treatment of MCF-7, MDA-
MB-231, HBL-100 and BT-549 cells with micromolar Oncamex
concentrations for 8 h induced concentration-dependent, inversely
correlated changes in cytotoxicity and cell viability, together with
caspase-3/-7 activation, consistent with apoptosis (Figure 3G).
Induction of apoptosis was also measured by western blotting
detection of PARP cleavage. Treatment with micromolar concen-
trations of AO-1530 or Oncamex led to cleavage of PARP.
Oncamex exerted a more rapid effect, with cleaved PARP being
detectable after 8 h, whereas 24-h incubation with AO-1530 was
required for PARP cleavage to occur (Figure 3F).
ROS modulation is linked to Oncamex’s properties. Oncamex
displays an active redox profile. Analysis of electrochemical activity
by cyclic voltammetry showed that Oncamex undergoes a
reversible reduction, with a midpoint potential of þ 145mV vs
normal hydrogen electrode (Supplementary Figure 4).
To assess the role of ROS modulation in Oncamex’s antitumour
effect, ApoTox assays were repeated with the addition of a 30-min
pre-incubation stage using an antioxidant agent (5 or 10mM
N-acetyl cysteine, NAC). Results with both model cell lines used
(MCF-7 and MDA-MB-231, selected to include both an ER-
positive and a triple-negative cell line, respectively) showed pre-
treatment with 10mM NAC caused a partial, but not complete,
blockage of the cytotoxic and apoptotic signals induced by
treatment with Oncamex (Figure 3H).
To investigate the effect of Oncamex on ROS production, MDA-
MB-231 cells (selected for their better adherence when grown on
coverslips) were stained with the novel fluorescent probes MitoPY1
or MitoSOX for the specific detection of mitochondrial hydrogen
peroxide (mH2O2) and superoxide (mSO), respectively. The signal
generated by MitoPY1 was not intense enough to allow for
sensitive quantification, but provided qualitative results in the form
of bright specks localised in the mitochondrial department.
The induction of mH2O2 was observed 1 h after treatment
with 0.3mM Oncamex but no significant signals arose after
longer incubations (Figure 4A). MitoSOX results showed a
quantifiable, significant increase in mSO production in cells
treated with higher concentrations of Oncamex for longer
treatment times (Figure 4B and C).
Oncamex induces gene expression changes related to cell cycle
and apoptosis regulation. Results from microarray experiments
showed that 6-h treatment with Oncamex altered the expression
profile of genes related to cell cycle and apoptosis (Figure 5). Genes
involved in cell cycle regulation were downregulated by treatment
in all cell lines studied. These include genes encoding proteins
with well-known biological functions such as cyclins (encoded by
CCND1, CCNF or CCNB1), regulators of proliferation (AURKA
and MKI67) and other cell division-promoting proteins (CDC20,
MCM5 or MCM3).
Functional enrichment analysis showed that Oncamex induces
different effects in two clusters of apoptosis-related genes.
Pro-apoptotic genes were upregulated by treatment, including
genes encoding apoptosis-inducing proteins (such as BNIP3,
15 min 1 h 6 h
15 min 1 h
×20 ×20 ×20
6 h
×100×100×100
Mitotracker Oncamex DAPI Mitotracker + Oncamex
Figure 2. Intracellular localisation of Oncamex. Fluorescence microscopy on MDA-MB-231 cells treated with Oncamex demonstrated the rapid
delivery of the drug and its localisation within the mitochondrial compartment, as shown by the overlap of the drug’s fluorescent signal with that
of Mitrotracker Deep Red (visualised as an orange–yellow signal resulting from the overlap of red and green fluorescences). The compound is
delivered to the mitochondria as early as 15min after the treatment and accumulates over time, retaining its organelle-specific targeting after 6 h.
Visualisation of the cells at higher magnifications showed the change in cell morphology after 6 h, indicative of the induction of apoptosis.
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BNIP3L or CRADD) and caspases (CASP7). Anti-apoptotic genes
were downregulated, including decreased expression of genes
involved in apoptosis inhibition (DFFA, BCL2, BIRC6 or BIRC5) or
survival and proliferation (IL10).
Oncamex inhibits tumour proliferation and viability in a mouse
in vivo model. Results from a first in vivo model in mice
implanted with MDA-MB-231 xenografts (selected for the better
ability of these cells to grow as xenografts) showed that treatment
with Oncamex (25mg kg 1 per day) had a significant effect
(Po0.05), inhibiting tumour growth as indicated by changes in
xenograft volume compared with untreated mice (Figure 6A).
Treatment did not entail significant changes in mean body weight
(o4% loss over 20 days) (Figure 6B).
IHC processing of collected xenograft tissue identified a
significant decrease in Ki-67 expression, from 60% in controls to
36% in mice treated with Oncamex (Figure 6C–F), suggesting that
this compound inhibits cell proliferation in vivo. Similarly, the
percentage of viable areas was significantly reduced from 56 to 37%
(Figure 6C–E and G).
DISCUSSION
In this study, we have identified several novel flavonoids with
greater potency than myricetin when assessed in a panel of seven
breast cancer cell lines. AO-1530, a synthetic analogue of myricetin
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Figure 3. Cytotoxic and apoptotic effects of Oncamex. Initial evidence on the mechanism of action of Oncamex was obtained from study of
breast cancer cell line models MCF-7 and MDA-MB-231. Microscopic visualisation of MCF-7 cells treated with 30mM Oncamex showed a reduction
in cell density, changes in cell morphology and the appearance of apoptotic and dead cells after 24 h (A–C), which was generalised by 72h after
treatment (D). CellTox Green plate assays supported preliminary results by direct measurement of the induction of cytotoxicity in treated MDA-
MB-231 cells, peaking 8h after treatment (E). Western blotting was used to measure PARP cleavage in treated MCF-7 cells (F): Oncamex seemed
to induce apoptosis faster, with PARP cleavage occurring after 8 h treatment with the highest concentrations, whereas 24-h incubation was
required with AO-1530. The 24-h incubation with the highest concentrations seemed to induce further cell degradation, preventing protein
detection. Apoptosis was confirmed by an additional method using ApoTox plate assays, which reported an dose-dependent increase in
cytotoxicity and apoptosis, inversely proportional to cell viability (G). These antitumour effects were partially blocked by 30 pre-treatment with
10mM of the antioxidant NAC (H).
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in which the non-redox-active OH groups on the A-ring of the
flavonoid have been removed and a decyl chain has been added to
improve cell membrane permeability (analogous to the function of
the chain in vitamin E), had previously been identified as a
more potent antioxidant than myricetin (McPhail et al, 2009).
Results from SRB assays have indicated that AO-1530’s strong
antiproliferative properties are surpassed by Oncamex, a second-
generation bi-methoxylated analogue.
We aimed to identify the SAR properties contributing to
the stronger potency of these novel analogues. The library of
compounds studied included molecules specifically designed to
achieve distinct intracellular targeting and effective redox proper-
ties. One of the defining characteristics of Oncamex is the inclusion
of two methoxy moieties in its structure. Previous research has
suggested contrasting effects of methoxy substitutions in chemical
entities: it has been reported that they may have unfavourable
steric effects, compromising redox-modulating and cytochrome
P450 (CYP1)-inhibitory capabilities (Heim et al, 2002; Arroo et al,
2009), while the extent of the BCRP-inhibitory properties of
flavonoids also depends on the number and location of these
modifications (Katayama et al, 2007; Pick et al, 2011; Tan et al,
2013). Nevertheless, the enhanced potency of Oncamex is most
likely the result of methoxylation leading to improved pharmaco-
kinetic properties and increased stability: methoxylated com-
pounds are less prone to modifications such as glucuronidation
and sulphation, and are thus more chemically and metabolically
stable (Androutsopoulos et al, 2010). Added to improved uptake
and membrane transport, such alterations may provide these
compounds with increased bioavailability (Walle, 2007; Arroo et al,
2009). Moreover, it has been reported that upon delivery,
methoxylated compounds are targeted by tumour-specific
O-demethylases that provide free hydroxyl groups and hence an
increase in redox properties (Androutsopoulos et al, 2008; Arroo
et al, 2009). Therefore, it seems reasonable that chain-bearing,
methoxylated novel flavonoids could make promising candidates
as potential chemotherapeutic agents, providing improved phar-
macological attributes, including cancer-specific activation.
Although Oncamex was the most potent compound in this
series, the effect of the other analogues was more variable.
Interestingly, the fully methoxylated molecule AO-714A showed a
potent effect with variable but generally low IC50 values. This also
supports the notion that flavonoids may not require free
hydroxyl groups to be active anticancer agents due to their
propensity to undergo demethylation in vivo by O-demethylases
(Arroo et al, 2009). Similar to Oncamex, AO-714A presents
multiple methoxylations that would improve its bioavailability and
these are located in the 30, 40 and 50 positions, reported as structural
features that significantly increase the BCRP-inhibitory activity of
flavonoids (Katayama et al, 2007; Tan et al, 2013). These
observations suggest that different mechanisms such as induction
of oxidative phosphorylation-independent cell death (as previously
reported with myricetin (Ko et al, 2005b)) could also be relevant to
their anticancer effect. Finally, other analogues expected to have a
redox potential comparable to that of AO-1530 but with no specific
targeting for mitochondria showed lower potency, highlighting the
importance of targeted drug delivery.
Overall, these results indicate that particular SARs are relevant
for the application of flavonoids to cancer treatment. The
antitumour effect of these novel molecules is most likely the result
of a combination of different structural traits and properties,
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including optimum redox potential and structural resemblance to
the flavonoid backbone, which has been shown to allow for a wide
range of molecular interactions for different polyphenols
(Martinez-Perez et al, 2014). In addition, the substitution with
electron-donating moieties, methoxylated residues and mitochon-
drial targeting provide significantly stronger antitumour
properties.
Oncamex exerts an antiproliferative effect on cancer cells and
has been found to induce apoptosis, as suggested by the
development of responses as soon as 8 h after treatment by
detection of caspase activation and PARP cleavage. Results from
the panel of breast cancer cell lines studied suggest that the
antitumour effect of Oncamex is independent of ER status, as
triple-negative cell lines MDA-MB-231, BT-549 and HBL-100 cells
showed susceptibility similar to that of ER-positive cells.
This suggests that Oncamex’s effect does not rely on modulation
of hormonal signals and thus may be applicable to cancers of a
more varied nature. We observed that LCC cell lines, which
are ER-positive but hormone-independent MCF-7 variants,
are less sensitive to Oncamex, but this is most likely due to the
lower baseline proliferation rate of LCC cells (Bru¨nner et al,
1993a, b, 1997).
The cytotoxic and apoptotic signals induced by Oncamex were
partially blocked by pre-incubation with an antioxidant, suggesting
that the compound’s redox activity, studied by electrochemical
analysis, is at least partially involved in the induction of these
responses through ROS modulation. The production of ROS was
detected by fluorescence microscopy using species-specific probes
to obtain in situ visualisation. Results reported the induction of
different mitochondrial ROS production in a concentration- and
time-dependent manner. Whereas mH2O2 was produced shortly
after treatment with nanomolar concentrations of Oncamex, mSO
was produced after 6 h treatment with higher concentrations, in the
same timeframe and concentration range linked to Oncamex’s
antitumour properties. The redox profile for Oncamex showed that
it undergoes a reversible reduction with a midpoint potential of
þ 145mV, a value substantially more positive than the physiolo-
gical resting redox potential in either cytoplasm or mitochondria
(Auchinvole et al, 2012; Mallikarjun et al, 2012). This supports the
notion that although aspects such as kinetics and biostability may
affect its reactivity, Oncamex would most likely be found in its
reduced form in the mitochondrial compartment and thus be able
to donate an electron to oxygen to form the superoxide radical
anion. Hence, results obtained from the study of mitochondrial
ROS suggest that production of superoxide in the mitochondrial
compartment might be associated with the antitumour effects
exerted but also support the existence of a biphasic effect,
previously reported for polyphenols such as flavonoids (Ramos,
2007), by which different, possibly opposing effects might be
exerted by a compound depending on a fine concentration balance.
Gene expression analysis was carried out to study the effect of
Oncamex on breast cancer cell line models at gene expression level.
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Cells were exposed to treatment levels that had been shown to exert
changes in proliferation and cell death, as well as to induce changes
in ROS signalling. Results supported the antiproliferative and pro-
apoptotic effects previously measured using cytotoxicity assays,
western blotting and different plate assays. This suggests that the
rapid delivery of Oncamex to the mitochondria is also translated
either directly or indirectly into regulation of these pathways at
gene expression level. Importantly, Oncamex induced largely the
same effect across different cell lines despite their inherent
biological differences.
The ROS status has been established as a major regulator in the
development and advancement of cancer and, as the site of cell
respiration, the mitochondrial compartment is the main source of
ROS-linked signalling. Hence, a number of different mechanisms
could be altered by the effect of these ROS-modulating drugs in the
mitochondria. Given the versatility of flavonoids as anticancer
agents, these results show that while Oncamex’s promise as an
antitumour agent has been demonstrated, its mechanism of action
is probably complex and further study will be required for a better
understanding.
Oncamex demonstrated significant growth-inhibitory activity in
the MDA-MB-231 breast cancer xenograft model at a dose level
that was not associated with any indications of toxicity. The
proliferative marker Ki-67 was reduced by treatment with the drug
consistent with an antiproliferative effect. Further studies are now
required to observe whether other breast cancer xenografts are
sensitive to this drug and to further study the pharmacokinetic and
pharmacodynamic properties of this agent.
In conclusion, we have shown the potential of the proto-
typic novel compound Oncamex as an antitumour agent. This
suggests that myricetin’s natural scaffold can be modified to
enhance its activity and shows the potential for mitochondrial
targeted, redox-active molecules in cancer therapy. The results
reported in this study have provided evidence of the anticancer
effect of Oncamex in in vitro cell culture models, as well as
preliminary antitumour activity in an in vivo xenograft model
in mice.
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